R&D Strength

We have established an efficient R&D system that enables us to continue to develop investigational drugs in high-potential therapeutic areas such as metabolic diseases, orthopedics, oncology and hematology. Through more than 30 years of accumulation, our R&D team has accumulated extensive professional knowledge in the fields of new drug discovery, efficacy evaluation, process and quality research, preclinical research, clinical research and regulatory filing.

Our R&D team has approximately 110 people, more than 60% of whom have master's and doctoral degrees, covering multi-disciplinary backgrounds. The main members of the R&D team have an average of more than 20 years of experience in the pharmaceutical industry. Due to our strong R&D capabilities, we participate in multiple national or provincial research projects. We have undertaken three major national science and technology projects, and our marketed products have won a total of 11 national honors. After 30 years of R&D efforts, we have established six product development platforms: recombinant protein drug technology platform, peptide drug technology platform, innovative drug-device combination technology platform, antibody drug technology platform, long-acting technology platform and subcutaneous drug delivery technology platform, allowing us to continue to develop and advance pipeline products.